Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor GTPase-activating protein 1 (ARFGAP1) is an enzyme that functions as a GTPase-activating protein (GAP) for ADP-ribosylation factor 1 (ARF1) and can also act on ARF-like protein Arl1[2][3][4][5]. ARFGAP1 is primarily localized to the Golgi apparatus, where it regulates vesicle trafficking by stimulating the hydrolysis of GTP bound to ARF1, leading to coat protein dissociation from Golgi-derived membranes—an essential step for vesicle fusion with target compartments[2][3][5][6][8]. The activity of ARFGAP1 is modulated positively by phosphoinositides and inhibited by phosphatidylcholine. The protein contains amphipathic lipid packing sensor motifs (ALPS), which enable it to sense membrane curvature and vesicle maturity[3]. Through its function, ARFGAP1 is a key regulator of protein and membrane transport in the early secretory pathway and the structure of the Golgi apparatus[3][5][8]. Although associated with some disease phenotypes such as cataracts, there is limited evidence for direct therapeutic targeting, interacting drugs, or use as a clinical biomarker[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor GTPase-activating protein 1 (ARFGAP1).